Research programme: antibacterial agents - Taxis Pharmaceuticals

Drug Profile

Research programme: antibacterial agents - Taxis Pharmaceuticals

Alternative Names: TXA 497; TXA 709; TXY 436; TXY 541

Latest Information Update: 12 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TAXIS Pharmaceuticals
  • Class Antibacterials
  • Mechanism of Action Bacterial FtsZ protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 07 Sep 2016 TXA 709 receives Qualified Infectious Disease Product status for Skin and soft tissue infections in USA
  • 05 Jun 2015 Pharmacokinetic, pharmacodynamic and efficacy data from preclinical studies released by Taxis Pharmaceuticals
  • 27 Apr 2015 Pharmacodynamics and immunogenicity data from a preclinical study in Bacterial infections presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top